Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection

Value in Health Regional Issues

Volumn 3, Issue 1, 2014, Pages 5-11

  McEwan, Philip ^a,b   Ward, Thomas ^b   Chen, Chien Jen ^c   Lee, Mei Hsuan ^c   Yang, Hwai I ^d   Kim, Ray ^e   L'Italien, Gilbert ^f,g   Yuan, Yong ^f  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^c ACADEMIA SINICA   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e Mayo Clinic   (United States)

^f Global Health Economics and Outcomes Research   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic; Cirrhosis; Fibrosis; Hepatocellular; Liver

Indexed keywords

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; INFECTION RATE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TAIWAN;

EID: 84896724246     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2013.08.001     Document Type: Article

References (19)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29(Suppl 1):74-81.
2. World Health Organization. Hepatitis C factsheet no. 164. July 2013. Available at: [Accessed October 9, 2013]. http://www.who.int/mediacentre/factsheets/fs164/en/.
3. Sievert W., Altraif I., Razavi H.A., et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(Suppl 2):61-80.
4. Lu S.N., Su W.W., Yang S.S., et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006, 119(8):1946-1952.
5. Freeman A.J., Dore G.J., Law M.G., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34(4, Pt 1):809-816.
6. Chen S.L., Morgan T.R. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3(2):47-52.
7. Sweeting M.J., De Angelis D., Brant L.J., et al. The burden of hepatitis C in England. J Viral Hepat 2007, 14(8):570-576.
8. Deuffic S., Buffat L., Poynard T., Valleron A.J. Modelling the hepatitis C virus epidemic in France. Hepatology 1999, 29(5):1596-1601.
9. Razali K., Thein H.H., Bell J., et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007, 91(2-3):228-235.
10. Brookmeyer R., Gail M. AIDS Epidemiology: A Quantitative Approach (Monographs in Epidemiology and Biostatistics) 1994, Oxford University Press, Inc, New York, NY.
11. Becker N., Marschner I., et al. A method for estimating the age-specific relative risk of HIV infection from AIDS incidence data. Biometrika 1993, 80(1):165-178.
12. Marschner I. On stochastic versions of the EM algorithm. Biometrika 2001, 88(1):281-286.
13. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MWR Recomm Rep 1998, 47(RR19):1-39. Centers for Disease Control and Prevention.
14. McEwan P., Kim R., Yuan Y. Assessing the cost utility of response guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Pol 2013, 11(1):53-63.
15. Thein H.H., Yi Q., Dore G.J., Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008, 48(2):418-431.
16. McGarry L.J., Pawar V.S., Panchmatia H.R., et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012, 55(5):1344-1355.
17. Lee S., Bain V., Peltekian K., et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006, 23(3):397-408.
18. Coffin P.O., Scott J.D., Golden M.R., Sullivan S.D. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012, 54(9):1259-1271.
19. Stein K., Dalziel K., Walker A., et al. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002, 6(31):1-122.